康龍化成(03759.HK):A股保薦代表變更為崔洪軍
格隆匯1月3日丨康龍化成(03759.HK)公佈,東方花旗作為公司首次公開發行股票並在創業板上市項目(A股上市)的保薦機構,指派荊飛、費春成為該項目的持續督導保薦代表人,持續督導期截至2022年12月31日。
近日,公司收到東方花旗《關於更換康龍化成(北京)新藥技術股份有限公司持續督導工作保薦代表人的函》,原保薦代表人費春成因工作變動原因,不再負責公司的持續督導保薦工作,為保證持續督導工作的有序進行,東方花旗委派保薦代表人崔洪軍接替費春成擔任公司持續督導期間的保薦代表人,履行對公司的持續督導職責。此次保薦代表人變更後,公司首次公開發行股票並在創業板上市項目(A股上市)的持續督導保薦代表人為崔洪軍先生和荊飛先生,持續督導期至2022年12月31日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.